Table 1.
Sociodemographic, biological, and clinical characteristics of seropositive and seronegative subjects by gender.
| HIV+ | HIV− | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Men (n = 57) | Women (n = 33) | F/χ 2 value | Men (n = 30) | Women (n = 31) | F/χ 2 value | |||||
| Mean | (SD) | Mean | (SD) | F | Mean | (SD) | Mean | (SD) | F | ||
| Age | 34.17 | (5.33) | 33.42 | (5.06) | .017 | 31.56 | (6.57) | 35.04 | (5.08) | .545 | |
| Years of education | 9.32 | (2.42) | 10.45 | (3.18) | .260 | 10.02 | (2.38) | 9.66 | (2.49) | .238 | |
| CD4 cells per m3 | 286.68 | (261.59) | 367.43 | (220.67) | 2.131 | — | — | — | — | — | |
|
| |||||||||||
| Variable | No. | (%) | No. | (%) | χ 2 | No. | (%) | No. | (%) | χ 2 | |
|
| |||||||||||
| Manual dominance | Right | 57 | (100.00) | 31 | (93.94) | .048 | 16 | (88.88) | 14 | (87.50) | .003 |
| Left | 0 | (0.00) | 2 | (6.06) | 2 | (11.12) | 2 | (12.50) | |||
| Drug | Never used drugs | 12 | (21.10) | 10 | (30.03) | .063 | 18 | (100.00) | 16 | (100.00) | .000 |
| Abuse | Abstinent IVDU* | 25 | (43.80) | 8 | (24.24) | — | — | — | — | ||
| Status | MMP* | 20 | (35.10) | 15 | (45.45) | — | — | — | — | ||
| Viral load | Not detectable | 14 | (24.60) | 11 | (33.30) | 1.214 | — | — | — | — | — |
| Low (<10,000) | 19 | (33.30) | 11 | (33.33) | — | — | — | — | |||
| Medium (from 10,000–30,000) | 7 | (12.30) | 3 | (9.09) | — | — | — | — | |||
| High (>30,000) | 17 | (29.80) | 8 | (24.25) | — | — | — | — | |||
| Antiretroviral therapy | Receiving | 55 | (96,49) | 32 | (96,96) | .000 | — | — | — | — | — |
| Not receiving | 2 | (3.51) | 1 | (3,03) | — | — | — | — | |||
| Phase of infection | Phase A | 16 | (28.10) | 14 | (42.42) | 1.281 | — | — | — | — | — |
| Phase B | 13 | (22.80) | 6 | (18.18) | |||||||
| Phase C | 28 | (49.10) | 13 | (39.40) | |||||||
∗ P < .05, ∗∗ P < .001.
*Note: IVDU: Intravenous Drug User; MMP: Methadone Maintenance Programme.